Table 2.
Treatment recommendations according to the different genotypes for patients with cirrhosis
| Treatment combination | Duration, weeks | TN | TE |
|---|---|---|---|
| Genotype 1 | |||
| SOF + SMV ± R | 12 or 24 | app | app |
| SOF + DCV ± R | 12 or 24 | app | app |
| SOF + LDV | 12 | app | nrec |
| SOF + LDV + R | 12 | rec | rec |
| SOF + LDV | 24 | rec | rec |
| SOF + LDV + R | 24 | app | app |
| PTV/r + OMV + DSV | 12 | app (1b) | app (1b) |
| PTV/r + OMV + DSV + R | 12 | rec (1b) | rec (1b) |
| PTV/r + OMV + DSV + R | 24 | rec (1a) | rec (1a) |
| Genotype 2 | |||
| SOF + R | 12 | rec | rec (16–24 weeks) |
| SOF + P/R | 12 | app | app |
| SOF + DCV ± R | 12 | nrec | app |
| Genotype 3 | |||
| SOF + R | 24 | rec | app |
| SOF + P/R | 12 | app | app |
| SOF + DCV + R | 24 | app | rec |
| Genotype 4 | |||
| SOF + LDV + R | 12 | rec | rec |
| SOF + LDV ± R | 24 | app | app |
| PTV/r + OMV + R | 24 | app | app |
| SOF + SMV ± R | 12 | app | app |
Rec = Recommended as first-line therapy; app = approved, but not recommended as first-line therapy; nrec = not recommended; TN = treatment-naïve; TE = treatment-experienced; SOF = sofosbuvir; SMV = simeprevir; R = ribavirin; P = pegylated interferon alpha; DCV = daclatasvir; LDV = ledipasvir; PTV/r = paritaprevir/ritonavir; OMV = ombitasvir; DSV = dasabuvir.